Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cyclerion Therapeutics Inc CYCN

Healthcare Biotechnology
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the... see more

Recent & Breaking News (NDAQ:CYCN)

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

GlobeNewswire June 6, 2022

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

GlobeNewswire May 4, 2022

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

GlobeNewswire February 24, 2022

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

GlobeNewswire February 23, 2022

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

GlobeNewswire February 1, 2022

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

GlobeNewswire January 26, 2022

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

GlobeNewswire November 11, 2021

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire November 9, 2021

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

GlobeNewswire September 22, 2021

Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 8, 2021

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

GlobeNewswire August 23, 2021

Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases

GlobeNewswire January 13, 2020

Cyclerion to Present at the J.P. Morgan Healthcare Conference

GlobeNewswire December 23, 2019

Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference

GlobeNewswire November 27, 2019

Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy

GlobeNewswire October 30, 2019

Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)

GlobeNewswire October 30, 2019

Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings

GlobeNewswire October 8, 2019

Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17

GlobeNewswire September 10, 2019

Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months

GlobeNewswire August 12, 2019

Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP

GlobeNewswire June 11, 2019